Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Ef
Go back to Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Ef| (NASDAQ: KOD) | Delayed: 89.50 -3.47 (3.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.97 | 52 Week High | $ | |||
| Open | $91.14 | 52 Week Low | $ | |||
| Day High | $94.64 | P/E | N/A | |||
| Day Low | $89.00 | EPS | $ | |||
| Volume | 577,779 | |||||



